Needham raised the firm’s price target on KalVista (KALV) to $32 from $28 and keeps a Buy rating on the shares. KalVista is being added to Needham’s Conviction List, replacing Liquidia (LQDA), given Yutepria’s growing uptake across pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. KalVista represents a compelling 2026-story given an attractive valuation that doesn’t yet reflect Ekterly’s initial launch success, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
- KalVista says MHLW in Japan grants marketing, manufacturing approval for Ekterly
- Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
- Pharvaris price target raised to $50 from $44 at Oppenheimer
- KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation